Jiayuh Lin, PhD

1. Li H., Liu A., Zhao Z., Xu Y., Lin J., Jou D., and Li, C. Fragment-based Drug Design and Drug Repositioning Using Multiple Ligand Simultaneous Docking (MLSD): Identifying Celecoxib and Template Compounds as Novel Inhibitors of STAT3. J. Medicinal Chemistry 54: 5592-5596 (2011).
2. Lin, L., Benson, D.M. Jr., DeAngelis, S., Bakan, C. E., Li, P-K., Li, C., and Lin, J. A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. International Journal of Cancer 130:1459-1469 (2012).
3. Liu, A., Liu, Y., Lin, L., Jin, Z., Yang, J., Hu, Q., Xu, Z., Wang, H., Li, C.,Lin, J. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. PloS ONE 7(10):e46624 (2012).
4. Yu W., Xiao H., Lin J., Li C. Discovery of Novel STAT3 Small Molecule Inhibitors via In Silico Site-Directed Fragment-Based Drug Design. J. Medicinal Chemistry 56:4402-4412 (2013).
5. Li H., Kumari V., Lin L., Jou D., Lin J., Li C. Drug Design Targeting Protein-Protein Interactions (PPIs) Using Multiple Ligand Simultaneous Docking (MLSD) and Drug Repositioning: Discovery of Raloxifene and Bazedoxifene as Novel Inhibitors of IL-6/GP130 Interface. J. Medicinal Chemistry 57:632-641 (2014).
6. Zhao C., Xiao H., Wu X., Li, C., Lin, J. Rational Combination of MEK inhibitor and STAT3pathway modulator for K-RAS mutant pancreatic and colon cancer cells. Oncotarget.  6:14472-87 (2015).
7. Zhao C, Li H, Lin HJ, Yang S, Lin J, Liang G. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism. Trends Pharmacol Sci. 37(1):47-61 (2016)
8. Wu X., Tang W., Marquez R., Li K^., Highfill C., He F., Lian J., Lin J., Fuchs J., Ji M., Li L., Xu L. Overcoming radiation resistance of pancreatic cancer by inhibiting STAT3 signaling. Oncotarget  7(10):11708-11723 (2016).

The research interests of my laboratory are focused on the roles of inflammatory Interleukin (IL)-6 family of cytokines IL-6 and IL-11 play in cancer. The IL-6 family of cytokines, in particular IL-6 and IL-11, is considered as one of the most important cytokine families during tumorigenesis and metastasis. IL-6 or IL-11 binds to its receptor then recruits Glycoprotein 130 (GP130) to form the heterotrimer and triggers a signaling cascade downstream including Signal Transducer and Activator of Transcription 3 (STAT3) and AKT pathways. Serum IL-6 and IL-11 levels in cancer patients are correlated with poor prognosis, advanced stage, and/or metastasis.

In addition, IL-6 and IL-11 signaling are involved in promoting proliferation, survival, Inflammation, invasion, and metastasis of cancer cells. One of the major downstream effectors of IL-6 and IL-11 is STAT3. Persistent activation of STAT3 is frequently detected in many types of human cancers. We are studying the mechanisms of IL-6 and IL-11 signaling in promoting cancer progression, survival, proliferation, and tumorigenesis. The laboratory is also developing novel structure-based design and drug repositioning of small molecule compounds as well as existing FDA-approved drugs that selectively target persistent IL-6/GP130 and IL-11/GP130 signaling in cancer cells as novel cancer therapeutic approaches. 

2010                Received an AACR top-rated abstract award at the AACR Annual Meeting in Washington D. C.  

2015                Feature Editorial Academy (Editorial Board) in May issue of the International Journal of Oncology. 

1. NIH/NCI R21 (PI-Lin)

2. NIH R01 (PI-Lin)

International Service

2012-2015              Review of research grant of the Health and Health Services Research Fund of the  Food and Health Bureau, Hong Kong SAR Government.

2012-present           International Journal of Biochemistry and Molecular Biology (ISSN: 2152-4114): Senior Editorial Board.

2013                       Review of a cancer research grant for the National Medical Research Council Ministry of Health, Singapore.

2014-Present          International Journal of Oncology: Editorial Academy (Editorial Board).

2014-present          BMC Cancer: Editorial Board.

National Service        

2005                       WISC grants reviewer, American Association for the Advancement of Science, Washington DC.    

2005-2010              The Congressionally Directed Medical Research Programs (CDMRP) Breast Cancer Research Program, Review Committee (Clinical and Experimental Therapeutics # 2 and # 4, and TRN1 panels).

2005-2008              External Consulting and Advisory Team Member, Global Clinical Development for    anti-cancer drugs, Global Health Sector, SRA, International, Inc., Fairfax, VA

2009-2010             NIH Special Emphasis Panel/Scientific Review Group 2009/10 ZRG1 OTC-K.

2013                      National Cancer Institute Special Emphasis Panel; ZCA1 SRLB-J (O1) S.

2013-2015             Pancreatic Cancer Action Network-AACR Research Grants Scientific Review Committee.

2013-present          American Journal of Cancer Research (ISSN: 2156-6976): Senior Editorial Board. 

2015-2016             Pennsylvania Department of Health: Serve as a final performance external reviewer of  a funded cancer research grant.

2016                      National Cancer Institute Special Emphasis Panel (SEP #5) for NCI Omnibus R21 and NCI Omnibus R03 grant reviews.

2017                      Invited by Cancer Drug Development & Therapeutics (CDDT) study section to review NIH applications from small business.

Local Service           

Institutional Service

 1999-2004          Search Committee for the recruitment of Gynecologic Oncology fellows, University of Michigan.

2000-2003           Medical Scientists Training program mentor, University of Michigan.

2000-2003           Research Executive Committee in the Department of OB/GYN at the University of Michigan

2000-2004           Cancer Biology Training Program mentor, University of Michigan.

2005                    Library oversight Committee, Department of Pediatrics, The Ohio State University.

2009-2010          Scholarship Oversight Committee Volunteer, Department of Pediatrics, The Ohio State University.

2010                   Annual Research retreat planning Committee, Department of Pediatrics, The Ohio State University.

2015-2016          Faculty Search Committee, Department of Pediatrics, The Ohio State University.

2016-present      Faculty Search Committee, Departments of Biochemistry and Molecular Biology and  Pathlogy, University of Maryland, School of Medicine.

Scientific judges for poster presentations

2005-2013   The Ohio State University Medical Center Annual Scientific Retreat.

2006-2007   The Ohio State University Comprehensive Cancer Center Annual Scientific Retreat.

2010-2015   The Research Institute at Nationwide Children’s Hospital, Columbus OH.

2013             IGP Symposium, The Ohio State University graduate Programs.

2013             OSBP graduate students recruitment and interviews.

2014             Denman Undergraduate Research Forum, The Ohio State University.

Graduate Student-Doctoral Committees, University of Michigan

Graduate Student-Doctoral Committees, The Ohio State University

Graduate Students-Thesis Advisor (Dr. Lin as the thesis advisor):

2004                   Ling Cen, Ph.D student, Ohio State Biochemistry Program, Ohio State University (Graduated in 2007): working at the Mayo Clinics, MN as a staff member.

2006                   Jacquie Lieblein, M.S. student, Ohio State Biochemistry Program, The Ohio State University (Graduated in 2008): became a Ph.D. student at the Ohio State Univ.

2006                   Matthew Sobo, M.S. student, MCDB, The Ohio State University (Graduated in 2010).

2008                   Sarah Ball, Ph.D student, MCDB, The Ohio State University (Graduated in 2011): teaching position at The Ohio State University.

International graduate Students-Ph.D. Thesis (Dr. Lin as the thesis co-advisor):

2012-2015          Chengguang Zhao, Ph.D. student, Nanjing University of Science and Technology, China.

2015-2016          Jilai Tian Ph.D. student, Southeast University, China.

Medical doctor Fellows- Lin Laboratory, University of Michigan (Dr. Lin as the mentor):

1999-2000           Melinda Huang, M.D. (Currently is a faculty member/physician in another  University/hospital)

2000-2001           William Burke, M.D. (Currently is a faculty member/physician in another University/hospital)

2001-2002           Thomas Reid, M.D. (Currently is a faculty member/physician in another University/hospital)

Medical doctor Fellows- Lin Laboratory, The Ohio State University (Dr. Lin as the thesis mentor):

2005-2007          Beng Huh, M.D. (Currently is a faculty member/physician in another University/hospital)

2006-2008          Jason Canner, M.D. (Currently is a faculty member/physician in another University/hospital)

2009-2010          Grace Ominoe, M.D. (Currently is a physician in another hospital)

2010-2011          Susan Reed, M.D. (Currently is a faculty member/physician at the Ohio State University/Nationwide Children’s Hospital)

2002-2003           Dana Gossett, M.D. (Currently is a faculty member/physician in another University/hospital)

1998-present           Full member, American Association for Cancer Research (AACR).

Major Invited Speeches 

International

2002    Lin J. “A novel AKT inhibitor targets endometrial cancer cells with PTEN mutation”, International Symposium on Cell and Molecular Biology of Endometrial Carcinoma, Kitasato Institute & University, Tokyo, Japan.

2002    Lin J.  “Target endometrial and ovarian cancer cells with a novel AKT inhibitor”, National Yang-Ming University, College of Medicine, Taipei, Taiwan.

2012    Lin J. “IL-6/STAT3 signaling in cancer”.  The German Cancer Research Center, Heidelberg, Germany